title: Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma.
abstract: OBJECTIVE
  Primary open-angle glaucoma (POAG), a chronic, degenerative optic neuropathy, requires persistent decrease of intraocular pressure so as to prevent visual impairment and blindness. However, long-term use of topical ocular medications may affect ocular surface health. Purpose of this study was to evaluate the influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed POAG.
  
  
  METHODS
  40 newly diagnosed POAG patients were included in this prospective study. Intraocular pressure (IOP), tear break-up time (TBUT), and ocular surface disease index (OSDI) were assessed at baseline and 3-month after starting treatment with BAK-preserved travoprost 0.004%.
  
  
  RESULTS
  IOP decreased in all patients from baseline to 3-month final visit (23.80 ± 1.73 mmHg versus 16.78 ± 1.27 mmHg; P < 0.001). Mean TBUT decreased from 11.70 ± 1.86 seconds at baseline to 8.30 ± 1.29 seconds at 3-month final visit (<0.001). Mean OSDI score increased from 31.63 ± 18.48 to 44.41 ± 16.48 (P < 0.001).
  
  
  CONCLUSIONS
  This study showed that BAK-preserved travoprost 0.004% is an effective medication in newly diagnosed POAG patients, but its long-term use may negatively influence ocular surface health by disrupting the tear film stability. Further studies are needed to better understand the clinical effects of different preservative types and concentrations on the ocular surface.
authors: Department of Ophthalmology, University Clinic Vuk Vrhovac, Clinical Hospital Merkur, Zagreb, Croatia. martina.tomic@idb.hr
authors: Martina
authors: M
authors: Tomić
authors: Snježana
authors: S
authors: Kaštelan
authors: Kata Metež
authors: KM
authors: Soldo
authors: Jasminka
authors: J
authors: Salopek-Rabatić
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017523:Croatia; D015352:Dry Eye Syndromes / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D005260:Female; D005902:Glaucoma, Open-Angle / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects / Q000627:therapeutic use; D000069557:Travoprost; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D011310:Preservatives, Pharmaceutical; D003008:Cloprostenol; D000069557:Travoprost
references: Arch Ophthalmol. 1994 Nov;112(11):1437-45
references: 7980133
references: Am J Health Syst Pharm. 2005 Apr 1;62(7):691-9
references: 15790795
references: Adv Ther. 2013 Mar;30(3):260-70
references: 23475405
references: Br J Ophthalmol. 2006 Mar;90(3):262-7
references: 16488940
references: Ocul Immunol Inflamm. 2007 Sep-Oct;15(5):389-93
references: 17972223
references: Cornea. 2008 Apr;27(3):339-43
references: 18362664
references: Ophthalmology. 2005 Jul;112(7):1177-85
references: 15921747
references: Arch Ophthalmol. 2002 Oct;120(10):1268-79
references: 12365904
references: Am J Ophthalmol. 1997 Dec;124(6):723-8
references: 9402817
references: Arch Ophthalmol. 1991 Aug;109(8):1090-5
references: 1867550
references: Adv Ther. 2001 Sep-Oct;18(5):205-15
references: 11783457
references: Clin Ophthalmol. 2009;3:291-5
references: 19668581
references: Curr Opin Ophthalmol. 2007 Mar;18(2):134-9
references: 17301615
references: Ophthalmology. 1992 Jul;99(7):1082-8
references: 1495787
references: Ophthalmology. 2011 Sep;118(9):1766-73
references: 21600658
references: Expert Opin Drug Saf. 2007 Jan;6(1):45-52
references: 17181451
references: Clin Ophthalmol. 2008 Mar;2(1):31-55
references: 19668387
references: Adv Ther. 2008 Aug;25(8):743-51
references: 18670744
references: Cornea. 2006 May;25(4):432-7
references: 16670481
references: Clin Ophthalmol. 2012;6:525-31
references: 22536047
references: BMC Ophthalmol. 2011 Jun 14;11:14
references: 21672240
references: Arch Ophthalmol. 1994 Nov;112(11):1446-54
references: 7980134
references: Br J Ophthalmol. 1975 Nov;59(11):667-9
references: 1203224
references: Am J Ophthalmol. 2005 Jun;139(6):999-1009
references: 15953429
references: Arch Ophthalmol. 2004 Apr;122(4):532-8
references: 15078671
references: Br J Ophthalmol. 2006 Nov;90(11):1370-3
references: 16825272
references: Drug Ther Bull. 2003 Feb;41(2):12-4
references: 12630335
references: Adv Ther. 2010 Nov;27(11):837-45
references: 20931366
references: Coll Antropol. 2013 Apr;37 Suppl 1:199-203
references: 23837244
references: J Glaucoma. 2008 Aug;17(5):350-5
references: 18703943
references: Bull World Health Organ. 2004 Nov;82(11):844-51
references: 15640920
references: Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
references: 12049574
references: Arch Ophthalmol. 2010 Jan;128(1):94-101
references: 20065224
references: Eur J Ophthalmol. 2007 May-Jun;17(3):341-9
references: 17534814